Corroborating this hypothesis, HIF-1, a transcriptional factor known to target glycolytic genes, accumulates under GLP-1R stimulation
Weight Loss Diabetes Drug Industry Leaders Eli Lilly Novo Nordisk Boehringer Ingelheim Amylin Pharmaceuticals Harman Finochem *Disclaimer: Major Players sorted in no particular order Recent Industry Developments April 2025: Drugmaker Eli Lilly announced that oral GLP-1 candidate orforglipron cut HbA1c by 1.31.6 points and induced 7.9% body-weight loss in Phase 3 trials
And the price, of course, was one problem
Unfortunately, due to the limited number of studies available, we could not provide a detailed subgroup analysis based on the specific GLP-1RAs classifications, procedure type, baseline patient characteristics, and the timing of therapy initiation
CNODES, Canadian Network for Observational Drug Effect Studies